Adefovir
- TRADE NAMES: Hepsera (Gilead); Preveon
- INDICATIONS: HIV infection, hepatitis B infection
- CLASS: Antiretroviral, Nucleotide analog reverse transcriptase inhibitor
- HALF-LIFE: 16–18 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amikacin, Amphotericin B, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Delavirdine, Drugs causing kidney toxicity, Foscarnet, Gentamicin, Hydroxyurea, Pentamidine, Tenofovir Disoproxil, Tobramycin
PREGNANCY CATEGORY: C
SEVERE ACUTE EXACERBATIONS OF HEPATITIS, NEPHROTOXICITY, HIV RESISTANCE, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of adefovir in the Informa Healthcare journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric